Behind HIMS's Big Move: Surprising Growth Potential Beyond GLP-1 Drugs
HIMS shows surprising growth potential that may not rely on GLP-1 drugs, indicating a promising trajectory for investors.
Latest news and analysis for Hims & Hers Health (HIMS).
HIMS shows surprising growth potential that may not rely on GLP-1 drugs, indicating a promising trajectory for investors.
HIMS faces regulatory scrutiny ahead of its Q4 earnings report, raising questions about future performance. Here's what investors need to know.
HIMS is making headlines with its $1.15 billion acquisition of Eucalyptus, poised to expand its international reach significantly.